"One of the inquiries we are repeatedly receiving is whether it is too late to file a lawsuit that could be part of this multi-district litigation," said Resource4thePeople. "The answer, in the overwhelming number of cases, is no."
"The federal judge in the case has not issued any order prohibiting additional claims being filed and, in his most recent ruling, found that plaintiffs' lawyers will be granted access to documents they were seeking, which means there will still be additional time before any trial is held."
Pradaxa’s manufacturer, Boehringer Ingelheim, has denied the claims that have been filed against them in the litigation,* including allegations contained in the complaints that the company was negligent by failing to adequately warn health care professionals and patients about bleeding side effects.
According to allegations in the Pradaxa multi-district litigation, the drug was approved by the FDA in 2010 as an improvement over another blood-thinner, warfarin, for patients vulnerable to atrial fibrillation.
Plaintiffs in the Pradaxa multi-district litigation are claiming that in cases of internal bleeding there is an antidote for warfarin but there is no antidote for Pradaxa and that in some cases deaths have occurred.
Bloomberg News, recently reported*** that Pradaxa “has been linked to more than 500 U.S. deaths over a two-year period.”
Bloomberg also reported*** that “Concerns about Pradaxa’s safety surfaced soon after U.S. doctors began prescribi
Copyright©2012 Vocus, Inc.
All rights reserved